Online citations, reference lists, and bibliographies.
← Back to Search

In Vitro Anti-mesothelioma Activity Of Cisplatin–gemcitabine Combinations: Evidence For Sequence-dependent Effects

I. Zanellato, Carla Doriana Boidi, G. Lingua, P. Betta, S. Orecchia, E. Monti, D. Osella
Published 2010 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PurposeThe present study addresses the optimization of gemcitabine–cisplatin protocols currently adopted in the clinical management of malignant pleural mesothelioma (MPM), using cell lines derived from different histological subtypes of MPM as an in vitro model.MethodsMPM cell lines were exposed either to single drugs or to their combinations, using a fixed dose ratio. Possible mechanisms for synergistic interactions were investigated by cell cycle analysis, western blot analysis of p53 phosphorylation status, and neutral comet assay to detect double strand breaks.ResultsFour-hour pre-treatment with gemcitabine followed by 68-h exposure to cisplatin was found to exert synergistic activity in both epithelioid and sarcomatoid MPM subtypes, inducing a strong S-phase arrest that correlated with accumulation of double-strand breaks (DSBs).ConclusionThe antiproliferative effects of the gemcitabine/cisplatin combination in mesothelioma cells can be maximized by pre-treatment with gemcitabine, suggesting that this drug increases cisplatin-induced DSBs by inhibiting DNA adduct repair.
This paper references
10.1038/onc.2008.315
The p53 family and programmed cell death
E. Pietsch (2008)
Synergistic interaction between cisplatin and gemcitabine in vitro.
A. Bergman (1996)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
10.1016/j.tig.2007.11.003
Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
D. T. Bergstralh (2008)
Pathology and genetics of tumours of the lung , pleura, thymus and heart
W. D. Travis (2004)
10.1002/14651858.CD009661
Excitatory amino acid inhibitors for traumatic brain injury
A. Gauden (2012)
10.1007/s12013-008-9039-y
Mechanisms of Dealing with DNA Damage-Induced Replication Problems
Magda Budzowska (2008)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1016/S0092-8674(00)80416-X
DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2
S. Shieh (1997)
10.1007/S00018-004-4174-0
Double-strand breaks: signaling pathways and repair mechanisms.
T. Karagiannis (2004)
Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells.
C. M. Sorenson (1988)
10.1016/S0959-8049(99)00004-0
Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
C. J. van Moorsel (1999)
10.1038/sj.bjc.6600174
Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications
L. Sigalotti (2002)
Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
L. Yang (2000)
10.1016/J.LUNGCAN.2006.04.014
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
G. Utkan (2006)
EVects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines
GJ Peters (2006)
10.1007/s11864-008-0071-3
Systemic Treatments for Mesothelioma: Standard and Novel
H. Kindler (2008)
ects of gemcitabine on cis - platinum - DNA adduct formation and repair in a panel of gemcitabine and cisplatin - sensitive or - resistant human ovarian cancer cell lines
GJ Peters (2006)
10.1038/sj.bjc.6690452
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
C. V. Moorsel (1999)
10.1016/J.BBAMCR.2007.05.002
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
M. Donadelli (2007)
10.3892/IJO.28.1.237
Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
G. Peters (2006)
10.1043/1543-2165(2008)132[397:AOITTD]2.0.CO;2
Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
A. Marchevsky (2008)
10.1111/j.1749-6632.1958.tb54909.x
AN EXPERIMENTAL DESIGN IN COMBINATION CHEMOTHERAPY
N. Mantel (1958)
World Health Organization Classification of Tumours
C. Fletcher (2002)
Participation of p53 protein in the cellular response to DNA damage.
M. Kastan (1991)
Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.
M. Reiss (1992)
10.1111/j.1349-7006.2007.00644.x
Clinical relevance of the homologous recombination machinery in cancer therapy
K. Miyagawa (2008)
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
V. Heinemann (1990)
10.1016/J.LUNGCAN.2004.04.027
Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance.
S. Orecchia (2004)
10.1016/0090-8258(88)90293-4
Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing.
B. U. Sevin (1988)
Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines.
W. Voigt (2000)
10.1093/ANNONC/MDJ941
Cellular pharmacology of gemcitabine.
E. Mini (2006)
10.1016/J.LUNGCAN.2007.09.018
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
10.1097/00001813-199906000-00003
Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
J. Padrón (1999)
10.1016/S0006-2952(02)01508-3
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.
M. Crul (2003)
10.1158/1078-0432.CCR-08-1579
Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma
F. Vandermeers (2009)
10.1111/j.1349-7006.2007.00669.x
Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross‐resistance to a wide range of DNA‐damaging drugs
Kei-ichi Ozaki (2008)
10.1002/jcp.10150
Synergistic effect of the anti‐HER‐2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines
S. Toma (2002)
10.1016/0065-2571(84)90007-4
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
T. Chou (1984)
10.1002/14651858.CD005574.PUB2
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
10.2174/187152007779314044
Biochemical mechanisms of cisplatin cytotoxicity.
V. Cepeda (2007)



This paper is referenced by
10.1016/J.ICA.2012.06.005
Metallo-drugs in the treatment of malignant pleural mesothelioma
I. Zanellato (2012)
10.1016/j.mrgentox.2011.01.010
Validation and application of Drosophila melanogaster as an in vivo model for the detection of double strand breaks by neutral Comet assay.
A. Sharma (2011)
10.1039/c7dt04614f
The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions.
E. Gabano (2018)
10.1002/cmdc.201100426
Evaluation of Platinum–Ethacrynic Acid Conjugates in the Treatment of Mesothelioma
I. Zanellato (2011)
10.1111/j.1476-5381.2012.01873.x
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
R. Favoni (2012)
10.1016/J.ICA.2015.03.039
Host–guest inclusion systems of Pt(IV)-bis(benzoato) anticancer drug candidates and cyclodextrins
M. Ravera (2015)
10.1016/j.tiv.2011.05.023
In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma.
S. Martinotti (2011)
Investigating heterogeneity of growth and drug response in mesotheliomas
Roxanne Otadoy (2013)
10.1016/j.jinorgbio.2014.07.018
Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
I. Zanellato (2014)
10.1039/c7dt01706e
How to obtain Pt(iv) complexes suitable for conjugation to nanovectors from the oxidation of [PtCl(terpyridine)].
E. Gabano (2017)
10.1097/JTO.0b013e3182653d31
DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy
N. Erčulj (2012)
10.1039/c3mt00117b
The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells.
I. Zanellato (2013)
10.1016/j.lfs.2018.08.048
A new platinum‐based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells
B. Rangone (2018)
10.1016/j.jinorgbio.2013.09.003
Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.
Manuela Alessio (2013)
10.3892/mmr.2013.1495
Sequence‑dependent effect of gemcitabine and cisplatin on A549 non‑small‑cell lung cancer cells.
Y. Tang (2013)
10.1155/2016/2380540
Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes
M. Ravera (2016)
10.1039/c2dt11874b
Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.
M. Ravera (2012)
Semantic Scholar Logo Some data provided by SemanticScholar